ALKERMES | ALKS - Cash And Equivalent


ALKERMES reported $616.45M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
AbbVie USD 5.23B 400M Dec/2025
Acadia Pharmaceuticals USD 847.02M 85.02M Sep/2025
ALKERMES USD 616.45M 95.25M Sep/2025
Amgen USD 9.13B 316M Dec/2025
Biogen USD 3.01B 854.3M Dec/2025
BioMarin Pharmaceutical USD 1.25B 36.29M Sep/2025
Bristol-Myers Squibb USD 10.21B 5.52B Dec/2025
Coherus Biosciences USD 103.35M 113.54M Sep/2025
Eli Lilly USD 7.27B 2.52B Dec/2025
Gilead Sciences USD 7.33B 2.19B Sep/2025
Heron Therapeutics USD 43.07M 26.55M Sep/2025
Ionis Pharmaceuticals USD 2.24B 1.94B Sep/2025
J&J USD 19.71B 1.48B Dec/2025
Malin Corporation EUR 62.1M 26.4M Dec/2024
Merck USD 18.17B 10.16B Sep/2025
Minerva Neurosciences USD 12.29M 2.96M Sep/2025
Nektar Therapeutics USD 41.03M 1.96M Sep/2025
Neurocrine Biosciences USD 713M 372.8M Dec/2025
Otsuka Holdings JPY 411.11B 3.62B Jun/2025
Pfizer USD 1.34B 295M Sep/2025
Regeneron Pharmaceuticals USD 18.87B 16.36B Dec/2025
Vertex Pharmaceuticals USD 6.61B 321.1M Dec/2025